BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25710583)

  • 1. The Differential Immunohistochemical Expression of p53, c-Jun, c-Myc, and p21 Between HCV-related Hepatocellular Carcinoma With and Without Cirrhosis.
    Abdou AG; Abd-Elwahed M; Badr M; Helmy M; Soliman EA; Maher D
    Appl Immunohistochem Mol Morphol; 2016 Feb; 24(2):75-87. PubMed ID: 25710583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus-NS3P in relation to p53, p21waf, mdm2, p21-ras and c-erbB2 in hepatocarcinogenesis.
    Bahnassi AA; Zekri AR; El-Houssini S; Mokhtar NM; Abdel-Aziz AO; Sherif GM; El-Mishad AM; Khaled HM
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1731-40. PubMed ID: 16246194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues.
    Niu ZS; Li BK; Wang M
    World J Gastroenterol; 2002 Oct; 8(5):822-6. PubMed ID: 12378623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
    Chan KL; Guan XY; Ng IO
    Hum Pathol; 2004 Nov; 35(11):1324-31. PubMed ID: 15668888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.
    Dixit U; Pandey AK; Liu Z; Kumar S; Neiditch MB; Klein KM; Pandey VN
    J Virol; 2015 Aug; 89(15):7905-21. PubMed ID: 25995247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.
    Chen Y; Lin C; Liu Y; Jiang Y
    Tumour Biol; 2016 Apr; 37(4):4399-408. PubMed ID: 26499944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis.
    Tretiakova MS; Shabani-Rad MT; Guggisberg K; Hart J; Anders RA; Gao ZH
    Histopathology; 2010 May; 56(6):683-93. PubMed ID: 20546333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
    Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
    Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
    Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
    J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
    El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
    APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
    Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
    Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
    Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.
    Watanabe T; Hiasa Y; Tokumoto Y; Hirooka M; Abe M; Ikeda Y; Matsuura B; Chung RT; Onji M
    PLoS One; 2013; 8(7):e67750. PubMed ID: 23844083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical detection of p21ras, c-myc and p53 oncoproteins in hepatocellular carcinoma and in non-neoplastic liver tissue].
    Pannain VL; Bottino AC; Santos RT; Coelho HS; Ribeiro-Filho J; Alves VA
    Arq Gastroenterol; 2004; 41(4):225-8. PubMed ID: 15806265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.
    Long J; Wang Y; Li M; Tong WM; Jia JD; Huang J
    Oncol Rep; 2013 Jul; 30(1):119-24. PubMed ID: 23624687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
    Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
    Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of p21WAF1/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases.
    Wagayama H; Shiraki K; Sugimoto K; Ito T; Fujikawa K; Yamanaka T; Takase K; Nakano T
    Hum Pathol; 2002 Apr; 33(4):429-34. PubMed ID: 12055678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus NS3 protein modulates the biological behaviors of malignant hepatocytes by altering the expression of host cell microRNA.
    Zhang J; Ishigaki Y; Takegami T
    Mol Med Rep; 2015 Oct; 12(4):5109-15. PubMed ID: 26151503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
    Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
    Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.